Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ZFV
|
|||
| Former ID |
DIB006626
|
|||
| Drug Name |
QPI-1007
|
|||
| Synonyms |
SiCASP2; SiRNA therapy (caspase-2, ocular injury), Quark Pharmaceuticals
Click to Show/Hide
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Ischemic optic neuropathy [ICD-11: 9C40.4] | Phase 3 | [1] | |
| Non-arteritic anterior ischemic optic neuropathy [ICD-11: 9C40.40] | Phase 3 | [2] | ||
| Glaucoma/ocular hypertension [ICD-11: 9C61; ICD-9: 365] | Phase 2/3 | [3] | ||
| Company |
Quark pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Caspase 2 messenger RNA (CASP2 mRNA) | Target Info | . | [4] |
| NetPath Pathway | TCR Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| Pathway Interaction Database | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| Caspase Cascade in Apoptosis | ||||
| Reactome | NOD1/2 Signaling Pathway | |||
| NADE modulates death signalling | ||||
| WikiPathways | Apoptosis Modulation by HSP70 | |||
| Apoptosis | ||||
| Parkinsons Disease Pathway | ||||
| Signalling by NGF | ||||
| Apoptosis Modulation and Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02341560) Phase II/III, Randomized, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION). U.S. National Institutes of Health. | |||
| REF 4 | Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014 Aug;24(4):258-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.